Heart Failure Reviews

, Volume 5, Issue 2, pp 167–173

Incidence and Epidemiology of Heart Failure

  • William B. Kannel
Article

Abstract

Epidemiologic data from the Framingham Study provide insights into the population burden of heart failure (CHF), its prognosis and modifiable risk factors that promote it. In the general population CHF is chiefly the end stage of hypertensive, coronary and valvular cardiovascular disease. It is a major and growing problem in most affluent countries because of aging populations of increased size, and the prolongation of the lives of cardiac patients by modern therapy. Once clinically manifest, CHF, despite recent innovations in therapy, carries an unacceptably high mortality rate. In the Framingham Study, median survival is only 1.7 y for men and 3.2 y for women, with only 25% of men and 38% of women surviving 5 y. This is a mortality rate 4–8 times that of the general population of the same age. This poor outlook is observed for all etiologies of CHF and sudden death is a prominent feature of the mortality. Based on population attributable risks, hypertension has the greatest impact, accounting for 39% of CHF events in men and 59% in women. Despite its much lower prevalence in the population (3–10%) myocardial infarction also has a high attributable risk in men (34%) and women (13%). Valvular heart disease only accounted for 7–8% of CHF. Hypertension increased the age and risk factor adjusted hazard of CHF 2-fold in men and 3-fold in women, with a greater impact of the systolic than diastolic blood pressure. Diabetes increased CHF risk 2–8 fold with risk ratios twice as large in women as men. About 19% of CHF cases have diabetes. It accounted for 6–12% of the CHF in the Framingham Study cohort. Dyslipidemia characterized by a high total/HDL cholesterol ratio, but not the total cholesterol alone was a risk factor for CHF. An enlarged heart on X-Ray, ECG-LVH, a reduced vital capacity and rapid heart rate usually signified deteriorating cardiac function. CHF risk associated with ECG-LVH was independent of X-Ray cardiomegaly but risk was further augmented when both coexist. Echocardiographic left ventricular hypertrophy signifies a high risk of CHF proportional to the degree of increase in left ventricular mass without a critical value that delineates compensatory from pathological hypertrophy. Risk of CHF in persons predisposed by hypertension, diabetes or cardiac conditions varies over a 10-fold range depending on the aforementioned modifiable risk factors and indicators of deteriorating left ventricular function. Using multivariate risk formulations it is possible to identify 20% of the population from which 70% of the CHF will evolve. Those in the upper quintile of multivariate risk are good candidates for echocardiographic testing to delineate those needing aggressive preventive measures to delay the onset of CHF. Therapy of CHF must begin with treatment of presymptomatic left ventricular dysfunction to reverse the dysfunctional maladaptive changes.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kannel WB and Belanger AJ. Epidemiology of heart failure. American Heart J, 1991;121(3):951–957.Google Scholar
  2. 2.
    The SOLVD Investigators. Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Eng J Med. 1992;327:685–691.Google Scholar
  3. 3.
    National Center for Health Statistics: Health, United States. 1995 DHHS No. (PHS) 96-1232. US Govt. Printing Office, 1996.Google Scholar
  4. 4.
    National Heart, Lung, and Blood Institute: Morbidity and Mortality Chartbook on Cardiovascular Lung and Blood Diseases. 1996. US Dept. of Health and Human Services.Google Scholar
  5. 5.
    Gillum RF. Epidemiology of heart failure in the United States. Amer Heart J 1993;126:1042–1047.Google Scholar
  6. 6.
    Ho KKL, Anderson KM, Kannel WB, Grossman Wand Levy D. Survival after the onset of heart failure in Framingham Heart Study subjects. Circ 1993;88:107–115.Google Scholar
  7. 7.
    Graves EG, Gillum BS:. 1994 Summary: National Hospital Discharge Survey: Advance Data. National Center for Health Statistics 1996;278:1–12.Google Scholar
  8. 8.
    Ranofsky A. Inpatient utilization of short stay hospitalizations by diagnosis. United States. 1971;National center for Health Statistics. DHEW Pub No. (HRA) 75-1767;1974.Google Scholar
  9. 9.
    Brown AM, Cleland JGF. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J. 1998;19:1063–1069Google Scholar
  10. 10.
    McMurray J, McDonough T, Morrison CE, et al. Trends for hospitalization for heart failure in Scotland. 1980-1990. Eur Heart J 1993;14:1158–1162.Google Scholar
  11. 11.
    Levy D, Larson MG, Vasan RS, Kannel WB and Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557–1562.Google Scholar
  12. 12.
    Kannel WB, Ho KKL and Thom T. Changing epidemiological features of cardiac failure. Brit Heart J 1995;72:S3–S9.Google Scholar
  13. 13.
    Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J AM Coll Cardiol 1993;22:6a–13a.Google Scholar
  14. 14.
    National Heart Lung and Blood Institute. Data Fact Sheet: Congestive Heart Failure in the United States: A New Epidemic. NHLBI Information center. P.O. Box 30105. Bethesda MD. 20804-0101. 1996.Google Scholar
  15. 15.
    Brophy JM. Epidemiology of congestive heart failure: Canadian data from 1970 to 1989. Can J Cardiol 1992; 8:495–498.Google Scholar
  16. 16.
    Ghandi MM. Clinical epidemiology of coronary heart disease in the UK. Br J Hosp Med 1997;58:23–27.Google Scholar
  17. 17.
    The CONSENSUS Trial study group (1987). Effect of enalapril on mortality in severe congestive heart failure. Results of the cooperative Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429–1435.Google Scholar
  18. 18.
    The acute Infarction Rampiril Efficacy Study (AIRE) Investigators. Effect of Rampiril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828.Google Scholar
  19. 19.
    Gillum RF. Idiopathic cardiomyopathy in the United States, 1970-1982. Am Heart J 1986;111:752–755.Google Scholar
  20. 20.
    Sugrue DD, Rodeheffer RJ, Codd MB, Ballard DJ, Fuster V, Gersh BJ. The clinical course of idiopathic dilated cardiomyopathy. Ann Intern Med 1992;117: 117–123.Google Scholar
  21. 21.
    Rakar S, Simagra G, Di Lenarda A, Poletti A, Bussani R, Silvestri F, Camerini F. The Heart Muscle Study Group. Epidemiology of dilated cardiomyopathy. A prospective postmortem study of 5252 necropsies. Eur Heart J 1997;18:117–123.Google Scholar
  22. 22.
    Levine SA. The value of determination of vital capacity of the lungs in the case of patients with heart disease. Arq Bras Cardiol 1949;2:253.Google Scholar
  23. 23.
    Kannel WB, D'Agostino RB, Silbershatz H. Use of vital capacity for cardiac failure risk estimation in persons with coronary disease and left ventricular hypertrophy. Am J Cardiol 1996;77:1155–1158.Google Scholar
  24. 24.
    Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension. The Framingham Study. Am Heart J 1993;125:1148–1154.Google Scholar
  25. 25.
    Kannel WB, Cupples LA. Epidemiology and risk profile of cardiac failure. Cardiovasc Drugs and Therapy 1988;2:387–395.Google Scholar
  26. 26.
    American Heart Association. 1997 Heart and Stroke: Statistical Update. Dallas TX.Google Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • William B. Kannel
    • 1
    • 2
  1. 1.Department of Preventive Medicine and Epidemiology, Evans Department of Clinical ResearchBoston University School of MedicineBoston
  2. 2.ASTRA USA, Hoechst Marion Roussel and Servier Amérique, Inc.USA

Personalised recommendations